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Abstract
Introduction The development of resistance by bacterial
species is a compelling issue to reconsider indications and
administration of antibiotic treatment. Adequate indications and
duration of therapy are particularly important for the use of highly
potent substances in the intensive care setting. Until recently, no
laboratory marker has been available to differentiate bacterial
infection from viral or non-infectious inflammatory reaction;
however, over the past years, procalcitonin (PCT) is the first
among a large array of inflammatory variables that offers this
possibility. The present study aimed to investigate the clinical
usefulness of PCT for guiding antibiotic therapy in surgical
intensive care patients.
Methods All patients requiring antibiotic therapy based on
confirmed or highly suspected bacterial infections and at least
two concomitant systemic inflammatory response syndrome
criteria were eligible. Patients were randomly assigned to either
a PCT-guided (study group) or a standard (control group)
antibiotic regimen. Antibiotic therapy in the PCT-guided group
was discontinued, if clinical signs and symptoms of infection
improved and PCT decreased to <1 ng/ml or the PCT value was
>1 ng/ml, but had dropped to 25 to 35% of the initial value over
three days. In the control group antibiotic treatment was applied
as standard regimen over eight days.
Results A total of 110 surgical intensive care patients receiving
antibiotic therapy after confirmed or high-grade suspected
infections were enrolled in this study. In 57 patients antibiotic
therapy was guided by daily PCT and clinical assessment and
adjusted accordingly. The control group comprised 53 patients
with a standardized duration of antibiotic therapy over eight
days. Demographic and clinical data were comparable in both
groups. However, in the PCT group the duration of antibiotic
therapy was significantly shorter than compared to controls (5.9
+/- 1.7 versus 7.9 +/- 0.5 days, P < 0.001) without negative
effects on clinical outcome.
Conclusions Monitoring of PCT is a helpful tool for guiding
antibiotic treatment in surgical intensive care patients. This may
contribute to an optimized antibiotic regimen with beneficial
effects on microbial resistance and costs in intensive care
medicine.
Annotation Results were previously published in German in
Anaesthesist 2008; 57: 571–577 (PMID: 18463831).
Trial registration ISRCTN10288268
Introduction
Early differentiation between sepsis and systemic inflamma-
tory response syndrome (SIRS) is of central importance for
therapeutic decision-making. Although patients with SIRS will
not require antibiotic therapy, immediate administration of anti-
biotics is essential for improved survival in patients with sepsis
[1]. Despite apparently clear sepsis definitions [2], early differ-
entiation between SIRS and sepsis is often difficult in clinical
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practice. SIRS criteria such as fever, tachycardia, and tachyp-
noea, are observed in most intensive care patients and are
fairly nonspecific features of various underlying diseases. On
the other hand, fever and leukocytosis may not necessarily be
present in clinically manifest sepsis [3,4]. Another problem for
the diagnosis of sepsis is the evidence of infection. In a pro-
spective study of 300 hospital patients with fever (>38.0°C),
Bossink and colleagues [5] were able to demonstrate that at
least two SIRS criteria were present in 95% of these patients
and clinical suspicion of sepsis in 71%, but only 44% had
microbiologic proven infection.
Besides profound clinical experience there is an urgent need
for biomarkers, which allow early differentiation between SIRS
and sepsis. Currently, procalcitonin (PCT) has emerged as a
laboratory variable that meets this demand [6]. Elevated PCT
values indicate systemic bacterial infections with high sensitiv-
ity. In their studies, Harbarth and colleagues [7] and Oberhof-
fer and colleagues [3] confirmed that monitoring of PCT
reliably differentiates SIRS and sepsis. Moreover, it was
recently shown, that PCT is a valuable tool to guide antibiotic
treatment in medical patients with pulmonary diseases [6,8,9].
However, there is no evidence in the literature about whether
this applies to antibiotic treatment in intensive care patients
with severe infections as well. In clinical practice, treatment
intervals of between 10 and 14 days are favored [10]. Unnec-
essarily long antibiotic administration is not only expensive, it
also leads to increased complications. Drug-induced side
effects, such as allergic reactions, antibiotic-associated colitis,
and the risk of life-threatening infections from multi-resistant
bacteria, significantly rise [11-13]. The causal relationship
between antibiotic use and antibiotic resistance has been well
established [14]. The frequency of multi-resistant pathogens
in patients undergoing long-term antibiotic therapy is clearly
increased [11]. In this context, newly arising fungal infections
in seven-day antibiotic treatment have become of great con-
cern, even in immunocompetent patients [15].
Therefore, we aimed to address the role of daily PCT-serum
determinations for guiding the length of antibiotic treatment in
surgical intensive care patients in the present randomized trial.
Materials and methods
Ethics commission approval was obtained from the Medical
Faculty at Christian Albrecht University of Kiel (A158/05) for
our trial in the surgical intensive care ward at the West Coast
Hospital Heide and written informed consent was obtained
from each individual. All patients requiring antibiotic therapy
based on confirmed or highly suspected bacterial infections
and at least two concomitant SIRS criteria were eligible [2].
Patients were randomly assigned to either a PCT-guided
(study group) or a standard (control group) antibiotic regimen.
For both groups, antibiotics were selected based on con-
firmed or highly suspected bacterial infections. The type of
antibiotic substance chosen was either calculated according
to the expected microbiologic spectrum and/or adjusted to the
isolated organisms whenever possible. IL-6, C-reactive protein
(CRP), PCT, and leukocyte count were determined daily for
each group on a routine laboratory basis. In addition, Sequen-
tial Organ Failure Assessment (SOFA) scores were calculated
daily [16] to stratify and monitor disease severity.
Antibiotic therapy in the PCT-guided group was discontinued
if clinical signs and symptoms of infection improved and PCT
decreased to less than 1 ng/ml, or if the PCT value was more
than 1 ng/ml, but had dropped to 25 to 35% of the initial value
over three days. In the control group, antibiotic treatment was
applied as standard regimen over eight days. Irrespective of
the study group and at any time point, the physician in charge
had the option to proceed with or adjust the antibiotic treat-
ment, if there were clinical reasons to do so.
IL-6 was measured by using the ACCESS® Immunoassay
(Beckman Coulter GmbH, Krefeld, Germany) and CRP was
measured by using the Vitros Chemistry System® 5.1 FF
(Ortho-Clinical Diagnostics GmbH, Neckargemünd, Ger-
many) according to the manufacturers' instructions. The leuko-
cyte count was analyzed with the Sysmex Hematology Device
(Sysmex Deutschland GmbH, Norderstedt, Germany). The
BRAHMS PCT LIA®  (BRAHMS Aktiengesellschaft, Hen-
nigsdorf, Germany) was used for the PCT determinations
according to manufacturers' protocols. The reference values in
healthy subjects for the aforementioned laboratory variables
are as follows: IL-6 less than 15 pg/ml, CRP less than 0.7 mg/
dl, PCT less than 0.5 ng/ml, and leukocytes 4 to 10 × 103/μl.
Clinical parameters such as age, gender, underlying diag-
noses, and the Simplified Acute Physiology Score (SAPS) II
for stratification of disease severity were documented in all
patients upon study inclusion. Throughout the study, the dura-
tion of intensive care stay and antibiotic treatment, all antibiotic
substance classes administered, and the outcome were
recorded.
Except when otherwise stated, continuous variables are pre-
sented as mean value and standard deviation for descriptive
statistics. Comparative statistics were performed by using the
Mann-Whitney-Wilcoxon U test. For comparison of propor-
tions (gender, diagnosis, antibiotic substance classes, sur-
vival/death) the chi-squared test was employed. A P < 0.05
was considered statistically significant.
Results
Of 395 patients screened, a total of 110 patients fulfilling the
inclusion criteria were entered in the study from January 2006
to March 2007. In these patients, a minimum of two SIRS cri-
teria were present at the start of antibiotic therapy due to a
confirmed or highly suspected bacterial infection. Patients
who refused study consent, whose antibiotic treatment hadAvailable online http://ccforum.com/content/13/3/R83
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been initiated before intensive care admission, or who had
therapy limitations were excluded from the study. Fifty-seven
patients were randomly assigned to the PCT-guided group
and 53 to the control group.
In the present prospective, randomised open study, both treat-
ment groups were comparable in terms of age, gender distri-
bution, diagnoses, disease severity as reflected by SAPS II,
and outcome (Table 1). The distribution of antibiotic classes
used was comparable as well (Table 2). The duration of antibi-
otic treatment in the PCT-guided group was with 5.9 ± 1.7
days significantly shorter than in the control group (P < 0.001)
with 7.9 ± 0.5 days without any negative effects on treatment
success (Tables 1 and 2). In addition, the length of intensive
care treatment in the PCT-guided group was 15.5 ± 12.5 days
and significantly shorter than that in the control group with
17.7 ± 10.1 days (P = 0.046; Table 1).
The SOFA score as a means to assess disease severity in
intensive care patients, the leukocyte count, as well as IL-6,
CRP, and PCT concentrations did not differ between the PCT-
guided and the control antibiotic treatment groups at any of
the time points the respective parameters were analyzed (Fig-
ures 1, 2, 3, 4 and 5). The only difference observed was in the
PCT-guided group, which revealed significantly lower PCT val-
ues compared with the initial values starting from the fourth
day of the study (Figure 6).
Discussion
Despite being considered as surrogate signs of systemic
inflammation, SIRS criteria are not always the result of a sys-
temic infection. They may arise due to general impairment of
the human organism [17]. Standard laboratory variables such
as CRP have a slow kinetic profile rendering it an inappropri-
ate marker for a fast evaluation of the dynamics of an infection
[18]. The same applies for the leukocyte count [3]. Further-
more, IL-6 levels are not indicators of infections or sepsis,
although they correlate well with the degree of severity of
inflammation [7].
Sepsis continues to be the leading cause of morbidity and in
its severe form (severe sepsis, septic shock, and multi-organ
dysfunction) of mortality in intensive care patients [19]. Treat-
ment is generally most effective if it is initiated without delay
according to current recommendations and guidelines. There-
Table 1
Demographic and clinical data
Controls PCT-guided antibiotic therapy P
Patients (n) 53 57
Age (years) 66.6 ± 15.5 67.3 ± 14.4 >0.05
Gender >0.05
Male 29 29
Female 24 28
Diagnoses >0.05
Pneumonia 19 24
Peritonitis 30 29
Soft tissue infection 1 2
Urosepsis 3 2
SAPS II 40.5 ± 15.1 40.1 ± 17.1 >0.05
Intensive care (days) 17.7 ± 10.1 15.5 ± 12.5 0.046
Hospital discharge >0.05
Survived 39 42
Deceased 14 15
PCT = procalcitonin; SAPS II = Simplified Acute Physiology Score II. Mean ± standard deviation.Critical Care    Vol 13 No 3    Hochreiter et al.
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fore, a fast and accurate diagnosis of infection and sepsis is of
central importance.
Harbarth and colleagues have convincingly shown that PCT
values differentiate patients with SIRS from those with sepsis.
Moreover, both PCT and IL-6 correlate with the systemic
severity of inflammatory response [7]. In the same study the
authors demonstrated that PCT rapidly decreased to refer-
ence values in successfully treated patients, whereas patients
with SIRS in the absence of infection revealed PCT values less
than 1 ng/ml throughout the clinical course. More recent stud-
ies suggest that a PCT-based algorithm significantly shortens
the length of antibiotic therapy without affecting the treatment
success and outcome [8,9].
Based on these data we hypothesized that the length of anti-
biotic therapy can be optimized and shortened in surgical
intensive care patients as well with daily PCT guidance. To
date, there is no evidence in the literature for this approach in
a surgical intensive care setting. In a study by Chastre and col-
leagues [11], 8-day and 15-day antibiotic therapy in patients
with respiratory-associated pneumonia and systemic sepsis
were compared. The authors did not observe any difference
between both groups in terms of treatment success. However,
the rate of recurrent infections with Pseudomonas aeruginosa
was greater for the eight-day treatment group, whereas a
markedly higher incidence of multi-resistant pathogens was
found in 60% of the reinfections in the 15-day treatment
group. Micek and colleagues [20] also studied the length of
antibiotic therapy in respiratory associated pneumonia and
postulated a therapeutic interval of seven to eight days as suf-
Table 2
Frequency of used antibiotics and length of therapy
Controls PCT-guided antibiotic therapy P
Antibiotic classes (%) >0.05
Acylaminopenicillin + BLI 51.8 55.2
Acylaminopenicillin + nitroimidazole 19.6 15.5
Carbapenem 8.8 10.4
Aminobenzylpenicillin + BLI 5.4 6.9
Fluorochinolone 5.4 5.2
Cephalosporins of Group 3b 5.4 3.4
Others 3.6 3.4
Length of antibiotic therapy (days) 7.9 ± 0.5 5.9 ± 1.7 <0.001
BLI = β-lactamase inhibitor; PCT = procalcitonin. Mean ± standard deviation.
Figure 1
Sequential Organ Failure Assessment scores Sequential Organ Failure Assessment scores. No difference in score 
was seen between patients with procalcitonin-guided antibiotic treat-
ment (filled columns) and the control group (empty columns). Mean ± 
standard deviation. SOFA = Sequential Organ Failure Assessment.
Figure 2
Leukocyte values Leukocyte values. No difference in values was seen between patients 
with procalcitonin-guided antibiotic treatment (filled columns) and the 
control group (empty columns). Mean ± standard deviation.Available online http://ccforum.com/content/13/3/R83
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ficient in responding patients. A prospective cluster-rand-
omized study by Christ-Crain and Müller [8] in more than 300
patients with community acquired pneumonia could show that
antibiotic treatment was reduced from 12 to 5 days by apply-
ing a PCT-based algorithm. Accordingly, Nobre and col-
leagues [9] could shorten the length of antibiotic therapy in
patients with sepsis using a PCT-based algorithm from a
median of 10 to 6 days without any influence on treatment out-
come. Based on the literature and study results on PCT-guid-
ance in intensive care patients with infections, a maximum
duration of antibiotic therapy of eight days appears to be suf-
ficient and safe.
The challenge of intensive care medicine is clearly the early dif-
ferentiation of patients with SIRS from those with sepsis.
Although this is mainly based on clinical course and symp-
toms, biochemical inflammation and sepsis markers are often
indispensable to establish diagnosis. However, despite these
limitations, a delayed start of antibiotic therapy should be
avoided whenever possible. A study from the USA was able to
demonstrate that patients with ventilator-associated pneumo-
nia who received antibiotic therapy only 24 hours after estab-
lished diagnosis, exhibited a seven times higher mortality rate
compared with patients started on adequate therapy earlier
[21]. Accordingly, Kumar and colleagues [1] could show that
the hospital mortality rate for patients with septic shock
increased by about 7% per hour within the first six hours of
delayed antibiotic administration.
The increasing resistance to standard antibiotics has driven
the need to revise treatment recommendations in terms of
diagnoses and duration of therapy. Current data have impres-
sively shown a dramatic increase of resistance against antibi-
otic groups by infectious micro-organisms [22]. Evidence from
the literature suggests that antibiotic therapy significantly
increases the risk of fungal infections, if administered for more
than seven days [15] and significantly increases the develop-
ment of resistance if applied for more than 10 days [10]. One
of the main reasons for the increasing rate of resistance is non-
controlled antibiotic use and long-term treatment in intensive
care wards [14,23]. The development of resistance is strongly
dependent on the antibiotic substance classes used, as well
as on the bacterium itself, and can last between one day and
three decades. Once resistance has emerged it is only slowly
or not reversible, even after changes in the selection pressure
Figure 3
IL-6 concentrations IL-6 concentrations. No difference in concentration was seen between 
patients with procalcitonin-guided antibiotic treatment (filled columns) 
and the control group (empty columns). Mean ± standard deviation.
Figure 4
C-reactive protein concentrations C-reactive protein concentrations. No difference in concentration was 
seen between patients with procalcitonin-guided antibiotic treatment 
(filled columns) and the control group (empty columns). Mean ± stand-
ard deviation. CRP = C-reactive protein.
Figure 5
Procalcitonin concentrations Procalcitonin concentrations. No difference in concentration was seen 
between patients with procalcitonin (PCT)-guided antibiotic treatment 
(filled columns) and the control group (empty columns). Mean ± stand-
ard deviation.Critical Care    Vol 13 No 3    Hochreiter et al.
Page 6 of 7
(page number not for citation purposes)
[14]. Therefore, it is postulated that both the early decision for
or against antibiotic therapy as well as a continuous re-evalua-
tion of the neccessity of anti-microbial therapy have a favorable
influence on this development. Singh and colleagues [12]
investigated intensive care patients with pneumonia and found
that discontinuing antibiotic treatment after three days in the
absence of a suspected infection did not worsen outcome.
This approach could reduce the development of resistance.
During the course of disease and treatment PCT-guided algo-
rithms can help to shorten the length of antibiotic therapy with-
out any unfavorable effects on treatment success and
outcome. This is well-documented in the literature and by our
own results [8,9].
Beyond a reduction of the length of antibiotic treatment PCT
guidance also had a favorable effect on the length of the inten-
sive care stay. These findings are in accordance with a recent
publication by Nobre and colleagues [9] who observed a
reduction of the length of antibiotic therapy along with a two-
day shorter average duration of intensive care treatment using
a PCT-based algorithm.
As already mentioned before, delayed diagnosis and inade-
quate antibiotic therapy have unfavorable consequences for
the success of treatment in patients with sepsis [1,11-13,15].
On the other hand, if antibiotic treatment is inadequate and too
long the development of antibiotic resistance is favoured
[11,14]. The duration of antibiotic therapy is based on the type
of infection, suspected or proven pathogens, and the clinical
course with potential recurrence of clinical signs and symp-
toms of infection. The length of treatment should be kept as
short as possible [10].
Conclusions
PCT assessment provides a helpful tool to decide on the dura-
tion of antibiotic treatment, if interpreted in the clinical context
including the underlying disease. This can substantially
improve to determine adequate duration of antibiotic therapy
with favorable effects on resistance and intensive care costs.
Competing interests
SS has served as consultant and has received payments from
BRAHMS AG for speaking engagements. All other authors
declare no conflicts of interest.
Authors' contributions
MH and SS conceived and designed the study, contributed to
acquisition, analysis and interpretation of data, performed the
statistical analysis, and drafted the manuscript. TK and AMS
made substantial contributions to data acquisition and inter-
Key messages
￿  PCT is the first laboratory marker among a large array of 
inflammatory variables that offers the possibility to differ-
entiate bacterial infection from viral or non-infectious 
inflammatory reaction.
￿  PCT assessment provides a helpful tool to decide on 
the duration of antibiotic treatment, if interpreted in the 
clinical context including the underlying disease.
￿  PCT-based algorithm supports the cautious use of anti-
biotics and has a favourable effect on the clinical out-
come.
￿  PCT-based algorithm is certainly practicable and sim-
ple.
￿  PCT-controlled antibiotic therapy must still be tested in 
heterogenous groups of patients, particularly for safety.
Figure 6
Procalcitonin levels solely shown for the intervention arm Procalcitonin levels solely shown for the intervention arm. In the group 
with procalcitonin (PCT)-guided antibiotic therapy duration, the PCT 
values starting on the fourth day are significantly lower in comparison to 
the initial value (box-plots with lower quartile, median and upper quar-
tile, 0.1- and 0.9-quantile for the whisker length and outliers as item 
representation). ￿ = Outliers, *P < 0.05.Available online http://ccforum.com/content/13/3/R83
Page 7 of 7
(page number not for citation purposes)
pretation, and revised the manuscript. BB and FSK contrib-
uted to study design and revised the manuscript. TvS
contributed substantially in all parts of the study and revised
the manuscript.
Acknowledgements
Results were previously published in Anaesthesist 2008; 57: 571–577 
(PMID: 18463831). For English publication the permission of Springer 
Science and Business Media was obtained.
References
1. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S,
Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M:
Duration of hypotension before initiation of effective antimi-
crobial therapy is the critical determinant of survival in human
septic shock.  Crit Care Med 2006, 34:1589-1596.
2. ACCP/SCCM Consensus Conference Committee: Definition for
sepsis and organ failure and guidelines for the use of innova-
tive therapies in sepsis.  Crit Care Med 1992, 20:864-874.
3. Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinkart K:
Outcome prediction by traditional and new markers of inflam-
mation in patients with sepsis.  Clin Chem Lab Med 1999,
37:363-368.
4. Peres Bota D, Lopes Ferreira F, Mélot C, Vincent JL: Body tem-
perature alterations in the critically ill.  Intensive Care Med
2004, 30:811-816.
5. Bossink A, Groen e v e l d  A ,  H a c k  C ,  T h i j s  L :  The clinical host
response to microbial infection in medical patients with fever.
Clin Infect Dis 1999, 29:398-407.
6. Christ-Crain M, Müller B: Procalcitonin in bacterial infections –
hype, hope, more or less?  Swiss Medical Weekly 2005,
135:451-460.
7. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau
GE, Vadas L, Pugin J, Geneva Sepsis Network: Diagnostic value
of procalcitonin, interleukin 6 and interleukin 8 in critically ill
patiens admitted with suspected sepsis.  Am J Respir Crit Care
Med 2001, 164:396-402.
8. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber
PR, Zimmerli W, Harbarth S, Tamm M, Müller B: Procalcitonin
guidance of antibiotic therapy in community – acquired pneu-
monia.  Am J Respir Crit Care Med 2006, 174:84-93.
9. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J: Use of procal-
citonin to shorten antibiotic treatment duration in septic
patients. A randomized trial.  Am J Respir Crit Care Med 2008,
177:498-505.
10. Welte T: Antibiotikatherapie bei Sepsis.  Dtsch Med Wochen-
schr 2004, 129:2609-2613.
11. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D,
Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F,
Aubas S, PneumA Trial Group: Comparison of 8 vs 15 days of
antibiotic therapy for ventilator-associated pneumonia in
adults: a randomized trial.  JAMA 2003, 290:2588-2598.
12. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL: Short-
course empiric antibiotic therapy for patients with pulmonary
infiltrates in the intensive care unit. A proposed solution for
indiscriminate antibiotic prescription.  Am J Respir Crit Care
Med 2000, 162:505-511.
13. Yu V, Singh N: Excessive antimicrobial usage cause measura-
ble harm to patients with suspected ventilator – associated
pneumonia.  Intensive Care Med 2004, 30:735-738.
14. Harbarth S: Antibiotikatherapie – Einfluss des Antibiotikaver-
brauchs auf Resistenzbildung und – selektion.  Anästhesiol
Intensivmed Schmerzther 2007, 2:130-135.
15. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J,
Caladra T, Glauser MP, Tauber MG, Pittet D: Fungal Infection
Network of Switzerland. Epidermiology of candidemia in
Swiss tertiary care hospitals: seculare trends, 1991–2000.
Clin Infect Dis 2004, 38:311-320.
16. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruin-
ing H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-
related Organ Failure Assessment) score to describe organ
dysfunction/failure. On behalf of the Working Group on Sep-
sis-Related Problems of the European Society of Intensive
Care Medicine.  Intensive Care Med 1996, 22:707-710.
17. Engelmann L: Die Diagnose der Sepsis.  In Diagnostik und Inten-
sivtherapie bei Sepsis und Multiorganversagen 1st edition. Edited
by: Engelmann L, Schuster H-P. Darmstadt: Steinkopff;
2006:2-10. 
18. Meisner M, Tschaikowsky K, Palmaers T, Schmidt J: Comparison
of Procalcitonin (PCT) and C-reactive protein (CRP) plasma
concentrations at different SOFA scores during the course of
Sepsis and MODS.  Critical Care 1999, 3:45-50.
19. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H,
Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K,
Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F,
Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K:
Epidemiology of sepsis in Germany: Results from a national
prospective multicenter study.  Intensive Care Med 2007,
33:606-618.
20. Micek S, Heuring TJ, Hollands JM, Shah RA, Kollef MH: Optimiz-
ing antibiotic treatment for ventilator-associated pneumonia.
Pharmacotherapy 2006, 26:204-213.
21. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH: Clinical
importance of delays in the initiation of appropriate antibiotic
treatment for ventilator-associated pneumonia.  Chest 2002,
122:262-268.
22. Meyer E, Jonas D, Schwab F, Gastmeier P, Rüden H, Daschner
FD: SARI: surveillance of antibiotic use and bacterial resist-
ance in German intensive care units. Correlation between anti-
biotic use and the emergence of resistance.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitss-
chutz 2004, 47:345-351.
23. Welte T: Die nosokomiale Pneumonie.  Intensivmed 2006,
43:301-309.